Scientific Papers
Selected peer-reviewed research and regulatory opinions on Antares Vitamin E TPGS, covering drug delivery, bioavailability enhancement, multidrug resistance, nutrition and safety. Click any title to view the original publication.
-
1
Safety evaluation of d-α-tocopheryl polyethylene glycol-1000 succinate (Vitamin E TPGS) as a food additive
EFSA FAF Panel (Castle L, et al.) EFSA Journal. 2025;23(8):e9605.
EFSA's food additives panel reviewed Vitamin E TPGS as a new emulsifier for foods. TPGS showed no genotoxicity and no reproductive or developmental effects at doses up to 1,000 mg/kg body weight per day. Using a margin-of-exposure approach, the panel concluded there is no safety concern at the proposed uses and use levels.
View publication → -
2
Exploring novel type of lipid-based drug delivery systems that contain one lipid and one water-soluble surfactant only
Dong X, Nguyen NTD. Int J Pharm. 2024;661:124447.
The authors screened libraries of lipids and water-soluble surfactants, including Vitamin E TPGS, to find simple two-component systems that form stable microemulsions. Several propylene glycol diesters and glycerol triesters worked well, and blends loaded onto a porous silica carrier formed solid granules. The results suggest these simple systems could allow higher drug loading in solid oral dosage forms.
View publication → -
3
Cationic Vitamin E-TPGS Mixed Micelles of Berberine to Neutralize Doxorubicin-Induced Cardiotoxicity via Amelioration of Mitochondrial Dysfunction and Impeding Apoptosis
Metwally AA, et al. Molecules. 2024;29(5):1155.
Researchers built positively charged TPGS-based mixed micelles to carry berberine to the mitochondria of heart cells. In cell studies, the berberine-loaded micelles protected heart muscle cells from doxorubicin damage better than free berberine. They preserved mitochondrial function and reduced markers of programmed cell death.
View publication → -
4
Vitamin E TPGS-Based Nanomedicine, Nanotheranostics, and Targeted Drug Delivery: Past, Present, and Future
Mehata AK, et al. Pharmaceutics. 2023;15(3):722.
This review traces TPGS from its development to its current role as an FDA-accepted excipient used in approved drug products. It surveys TPGS-based nanomedicine and theranostic platforms that improve drug solubility, extend circulation time, target tumors and help counter P-glycoprotein-linked multidrug resistance. Preclinical studies, clinical trials and patents are also covered.
View publication → -
5
Water-soluble tocopherol derivatives inhibit SARS-CoV-2 RNA-dependent RNA polymerase
Pacl HT, et al. bioRxiv [Preprint]. 2021 Jul 14:2021.07.13.449251. PMID: 34282419; PMCID: PMC8288149.
An AI-guided screen and laboratory testing identified water-soluble vitamin E derivatives, notably TPGS, as inhibitors of SARS-CoV-2. TPGS also acted against related coronaviruses and enhanced the activity of remdesivir. The compounds appear to block the virus's replication enzyme. This is a preprint that had not been peer reviewed when posted.
View publication → -
6
Novel Vitamin E TPGS based docetaxel nanovesicle formulation for its safe and effective parenteral delivery: Toxicological, pharmacokinetic and pharmacodynamic evaluation
Singh A, et al. J Liposome Res. 2021;31(4):365-380.
The authors replaced the polysorbate 80 used in commercial injectable docetaxel with a TPGS-based nanovesicle formulation (about 100 nm, more than 95% drug encapsulation). In mice it was tolerated at much higher doses than the commercial product (138 vs. 40 mg/kg). It also inhibited tumor growth by about 76% in a carcinoma model.
View publication → -
7
Pulmonary Delivery of Reactive Oxygen Species/Glutathione-Responsive Paclitaxel Dimeric Nanoparticles Improved Therapeutic Indices against Metastatic Lung Cancer
Tian X, et al. ACS Appl Mater Interfaces. 2021;13(48):56858-56872.
Paclitaxel dimers joined by disulfide linkers were assembled into nanoparticles with Vitamin E TPGS for delivery to the lungs. The particles released drug in response to the tumor's redox environment and stayed in the lungs longer. In mice with lung metastases, delivering them into the airway outperformed intravenous Taxol, with far less systemic and lung toxicity.
View publication → -
8
Progress in the study of D-α-tocopherol polyethylene glycol 1000 succinate (TPGS) reversing multidrug resistance
Yan H, et al. Colloids Surf B Biointerfaces. 2021;205:111914.
Multidrug resistance, often driven by the P-glycoprotein efflux pump, is a leading cause of chemotherapy failure. This review explains how TPGS can both inhibit P-glycoprotein and serve as a drug carrier. It summarizes recent TPGS-based nanodelivery systems designed to overcome resistance.
View publication → -
9
A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb® Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects
Knaub K, et al. Molecules. 2019;24(16):2967.
In a randomized, double-blind crossover study of 16 healthy adults, a self-emulsifying cannabidiol (CBD) formulation was compared with a standard oil-based product. The self-emulsifying version gave a 4.4-fold higher peak blood level, reached in about 1 hour instead of 3. Overall exposure was 2.85-fold higher over 8 hours, and no safety concerns were seen.
View publication → -
10
Major engine of growth in the cannabis industry: State of the art formulation technology for product innovation and expanded applications
Papas AM. Cannabis Science and Technology. 2018;1(4):56-59.
This article argues that formulation science drives innovation in cannabis products, because CBD and THC oils are poorly water-soluble and easily degraded. It reviews solubilizers, absorption enhancers and stabilizers. It highlights Vitamin E TPGS for its safety record, its micelle-forming absorption benefits and its antioxidant contribution to product stability.
View publication → -
11
Recent Advances in the Application of Vitamin E TPGS for Drug Delivery
Yang C, Wu T, Qi Y, Zhang Z. Theranostics. 2018;8(2):464-485.
This review describes TPGS as an FDA-accepted excipient that improves drug solubility and permeability, inhibits P-glycoprotein and shows selective activity against tumor cells. It surveys TPGS-based prodrugs, polymers and nanoformulations. It also discusses the challenges of moving them into clinical use.
View publication → -
12
Role of P-Glycoprotein Inhibitors in the Bioavailability Enhancement of Solid Dispersion of Darunavir
Rehman S, et al. Biomed Res Int. 2017;2017:8274927.
To improve oral absorption of the poorly soluble HIV drug darunavir, the authors prepared solid dispersions containing a P-glycoprotein inhibitor (Kolliphor TPGS or Soluplus). Intestinal uptake and animal studies showed that TPGS markedly increased absorption and bioavailability by limiting drug efflux.
View publication → -
13
TPGS-chitosome as an effective oral delivery system for improving the bioavailability of Coenzyme Q10
Shao Y, Yang L, Han HK. Eur J Pharm Biopharm. 2015;89:339-46.
Chitosan-coated TPGS liposomes (TPGS-chitosomes) were developed for oral coenzyme Q10. They increased uptake in intestinal cells about 30-fold compared with untreated powder. In rats they raised systemic exposure 3.4-fold, with sustained release over 24 hours and stronger antioxidant effects.
View publication → -
14
A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer
Bu H, et al. Int J Pharm. 2014;471:206-13.
A self-assembled paclitaxel nanoemulsion containing TPGS (droplets of about 25 nm) reversed resistance in drug-resistant breast cancer cells, likely by suppressing P-glycoprotein. In tumor-bearing mice it achieved about 94% tumor inhibition, with tumors roughly one-tenth the size of those treated with standard paclitaxel.
View publication → -
15
Solid self-emulsifying drug delivery system (S-SEDDS) for improved dissolution rate of fenofibrate
Kanaujia P, Ng WK, Tan RB. J Microencapsul. 2014;31(3):293-8.
Solid self-emulsifying formulations of fenofibrate were prepared and compared with TPGS-containing versions. When dispersed in water they formed nanoemulsions of about 150–200 nm. The best formulations released 90–100% of the drug within 60 minutes, versus 2–4% for untreated fenofibrate.
View publication → -
16
Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity
Collnot EM, et al. Mol Pharm. 2007;4(3):465-74.
This study investigated how TPGS blocks the P-glycoprotein drug efflux pump. Changes in membrane fluidity occurred only at concentrations well above those needed for inhibition, so they were ruled out as the main mechanism. Instead, TPGS inhibited the pump's ATPase energy source, and ATPase inhibition tracked closely with efflux inhibition across TPGS analogues.
View publication → -
17
D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) in use for food for particular nutritional purposes
EFSA. EFSA Journal. 2007;490:1-20.
EFSA assessed TPGS for use in foods for special medical purposes under medical supervision. Based on a no-observed-effect level of 1,000 mg/kg body weight per day, estimated intakes provided an adequate safety margin. The panel noted that TPGS adds little vitamin E for healthy people and advised caution in children with severe kidney impairment.
View publication → -
18
Multicenter trial of d-alpha-tocopheryl polyethylene glycol 1000 succinate for treatment of vitamin E deficiency in children with chronic cholestasis
Sokol RJ, et al. Gastroenterology. 1993;104(6):1727-35.
At eight U.S. centers, 60 children with chronic cholestasis whose vitamin E deficiency did not respond to standard oral vitamin E were treated with TPGS. All reached normal vitamin E levels. Over about 2.5 years, neurological function improved or stabilized in nearly all patients, and no adverse effects were observed.
View publication → -
19
Efficacy of absorption of various vitamin E forms by captive elephants and black rhinoceroses
Papas AM, Cambre RC, Citino SB, Sokol RJ. J Zoo Wildl Med. 1991;22(3):309-317.
Captive elephants and black rhinoceroses had persistently low blood vitamin E levels despite supplementation with standard vitamin E acetate. Fat-soluble and water-dispersible forms raised levels little, even at high doses. Water-soluble TPGS was readily absorbed and raised blood levels at several-fold lower doses.
View publication →
Summaries are prepared by Antares Health Products for convenience. Please refer to each original publication for the full abstract and results.